业已证实秋水仙碱是胶原合成的抑制剂,用秋水仙碱治疗肝硬化可能有效。方法用随机双盲对照法对100例肝硬化病人,用秋水仙碱1mg/d,每周5天治疗者54例,对照组46例。随访达14年之久。酒精性肝硬化45例,治疗组24例,对照组21例。肝炎后肝硬化41例,治疗组25例,对照组16例。92%病例曾作肝组织活检。Child-Turcotle分级:A级73例,治疗组39例,对照组34例;B级26例,治疗组15例,对照组11例;C级1例为对照组。结果中数存活期:治疗组11年,对照组3.5年(P<0.001)。累积5年存活率治疗组75%,对照组34%。10年存活率治疗组56%,对照组20%。治疗组中30例曾反复作肝组织活检,组织学上有改善者9例,肝组织正常者2例,呈轻度门脉区纤维化者7例,对照组14例进行过2次以上肝活检者,无1例有组织学进步。讨论本文结果看出秋水仙碱对延长肝硬化病人寿命有效。未见到秋水仙碱的治疗反应与肝硬化病因有关。几世纪以来秋水仙碱作为抗炎剂用于急性痛风 Colchicine has been shown to be an inhibitor of collagen synthesis and colchicine treatment of cirrhosis may be effective. Methods 100 cases of cirrhosis patients were treated with colchicine 1 mg / d by randomized double-blind control method, 54 cases were treated 5 days a week and 46 cases were control group. Followed up for 14 years. 45 cases of alcoholic cirrhosis, 24 cases in the treatment group and 21 cases in the control group. 41 cases of posthepatitic cirrhosis, 25 cases in treatment group and 16 cases in control group. 92% of cases had liver biopsy. Child-Turcotle grading: A grade 73 cases, treatment group 39 cases, control group 34 cases; B class 26 cases, treatment group 15 cases, control group 11 cases; C grade 1 case as control group. The median survival was 11 years in the treatment group and 3.5 years in the control group (P <0.001). The cumulative 5-year survival rate was 75% in the treatment group and 34% in the control group. The 10-year survival rate was 56% in the treatment group and 20% in the control group. Thirty cases in the treatment group were repeatedly biopsied for liver biopsy. There were 9 cases with histological improvement, 2 cases with normal liver tissue, 7 cases with mild portal fibrosis and 14 cases with control group with 2 or more liver Biopsy, no case of histological improvement. Discussion of the results of this paper shows colchicine to extend the life of patients with liver cirrhosis. Colchicine did not see the response to treatment and cirrhosis of the cause. Colchicine has been used as an anti-inflammatory agent for acute gout for centuries